BRIEF published on 05/08/2024 at 07:35, 2 years 4 months ago Formycon annonce des performances stables au premier trimestre 2024 malgré les défis Formycon AG Résultats Financiers Du Premier Trimestre 2024 Développement De Biosimilaires Partenariat Gédéon Richter Marché Biopharmaceutique
PRESS RELEASE published on 05/08/2024 at 07:30, 2 years 4 months ago Formycon reports on successful operating business and financial figures for the first quarter of 2024 Formycon reports successful Q1 2024 operating business and financial figures, including acquisitions and strategic investments. Revenue at €17.7 million. Invitation to conference call Acquisitions Financial Figures Strategic Investments Q1 2024 Formycon
BRIEF published on 05/07/2024 at 11:05, 2 years 4 months ago Formycon Announces Key Details for Annual General Meeting 2024 and Changes in Supervisory Board Annual General Meeting Corporate Governance Supervisory Board Formycon AG Biosimilars
BRIEF published on 05/07/2024 at 11:05, 2 years 4 months ago Formycon annonce les détails clés de l'Assemblée générale annuelle 2024 et des changements au sein du conseil de surveillance Gouvernance D'Entreprise Formycon AG Conseil De Surveillance Assemblée Générale Annuelle Biosimilaires
PRESS RELEASE published on 05/07/2024 at 11:00, 2 years 4 months ago Formycon invites to the Annual General Meeting on June 12, 2024 in Munich Formycon AG invites shareholders to Annual General Meeting in Munich on June 12, 2024, to elect new Supervisory Board members and expand the board to enhance international focus and expertise Annual General Meeting Financial Expertise Supervisory Board Formycon AG International Focus
BRIEF published on 05/02/2024 at 07:35, 2 years 5 months ago Formycon AG Announces First Quarter 2024 Conference Call Conference Call Investor Conferences Formycon AG Financial Outlook Q1 2024 Results
BRIEF published on 05/02/2024 at 07:35, 2 years 5 months ago Formycon AG annonce une conférence téléphonique pour le premier trimestre 2024 Formycon AG Conférence Téléphonique Perspectives Financières Conférences Investisseurs Résultats Du Premier Trimestre 2024
PRESS RELEASE published on 05/02/2024 at 07:30, 2 years 5 months ago Formycon hosts conference call on the results of the first quarter 2024 Formycon AG to host conference call discussing first quarter 2024 results, financial figures, and 2024 outlook. Management to participate in investor conferences globally Conference Call Investor Conferences Financial Figures Formycon AG First Quarter 2024 Results
BRIEF published on 04/25/2024 at 07:35, 2 years 5 months ago Formycon Announces Strong Financial Results for 2023 and Provides Outlook for 2024 2024 Outlook Formycon AG Biosimilars 2023 Financial Results Biopharmaceuticals
BRIEF published on 04/25/2024 at 07:35, 2 years 5 months ago Formycon annonce de solides résultats financiers pour 2023 et fournit des perspectives pour 2024 Perspectives 2024 Formycon AG Résultats Financiers 2023 Produits Biopharmaceutiques Biosimilaires
Published on 10/05/2026 at 22:30, 1 hour 4 minutes ago EV Nickel Announces Formation of Wholly Owned Subsidiary to Advance Nickel Bioleaching Technology and Canadian Nickel Supply Chain
Published on 10/05/2026 at 14:45, 8 hours 49 minutes ago NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Published on 10/05/2026 at 14:30, 9 hours 4 minutes ago Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Published on 10/05/2026 at 14:30, 9 hours 4 minutes ago Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Published on 10/05/2026 at 14:00, 9 hours 34 minutes ago Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
Published on 10/05/2026 at 22:25, 1 hour 8 minutes ago LumApps Named a Leader in 2026 Gartner® Magic Quadrant™ for Intranet Packaged Solutions
Published on 10/05/2026 at 22:05, 1 hour 28 minutes ago AMPERA SUBMITS COMPREHENSIVE ENGAGEMENT PLAN TO THE U.S. NUCLEAR REGULATORY COMMISSION
Published on 10/05/2026 at 21:10, 2 hours 24 minutes ago Shelly Group Board of Directors considers EUR 70.00 offer price fair and supports Schneider Electric’s voluntary public tender offer
Published on 10/05/2026 at 21:05, 2 hours 28 minutes ago EQS-Adhoc: Shelly Group SE: Board of Directors with positive opinion on the registered voluntary public tender offer by Schneider Electric SE
Published on 10/05/2026 at 20:15, 3 hours 18 minutes ago EQS-Adhoc: United Internet AG participates in capital increase against contributions in kind at 1&1 AG
Published on 10/05/2026 at 22:12, 1 hour 21 minutes ago AXA - Elimination of the dilutive impact of Shareplan 2026
Published on 10/05/2026 at 22:12, 1 hour 21 minutes ago AXA - Elimination de l'effet dilutif de l'opération Shareplan 2026
Published on 10/05/2026 at 18:13, 5 hours 21 minutes ago Disclosure of shares outstanding and voting rights - 05.10.2026
Published on 10/05/2026 at 18:13, 5 hours 21 minutes ago Déclaration nombre d'actions et droits de vote - 05.10.2026
Published on 10/05/2026 at 18:00, 5 hours 34 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 septembre 2026
